• 31161 Citations
  • 75 h-Index
1978 …2021
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where David R Gandara is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 21 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Cisplatin Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Small Cell Lung Carcinoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1988 2021

CANCER CENTER SUPPORT GRANT-P30

DeGregorio, M., Matthews, D., Felton, J. S., deVere White, R. W., Radke, K., Lloyd, K. K., Gandara, D. R., Beckett, L. A., Gregg, J., Luciw, P. A., Kung, H., Gumerlock, P. H., Mack, P., Evans, C. P., Lara, P. N., Lam, K., Chen, X., Kelly, K., Cherry, S. R., Shacklett, B., Lloyd, K. C. K. & Chen, M.

National Institutes of Health

7/1/026/30/21

Project: Research project

Neoplasms
Organized Financing
Research
Research Personnel
Clinical Trials

UCDCCC NCTN UG1 PROGRAM

Gandara, D. R.

Project: Research project

UCDCCC NCTN U10 Program

Gandara, D. R. & Valicenti, R.

National Institutes of Health

4/14/142/28/19

Project: Research project

Neoplasms
Research Personnel
Clinical Trials
Clinical Nursing Research
Biostatistics

Research Output 1978 2019

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

Xie, H., Yin, J., Shah, M. H., Menefee, M. E., Bible, K. C., Reidy-Lagunes, D., Kane, M. A., Quinn, D. I., Gandara, D. R., Erlichman, C. & Adjei, A. A., Jan 1 2019, In : Investigational New Drugs.

Research output: Contribution to journalArticle

Gossypol
Adrenocortical Carcinoma
Troponin
Hypokalemia
B-Cell Lymphoma

Challenges and approaches to implementing master/basket trials in oncology

Burd, A., Schilsky, R. L., Byrd, J. C., Levine, R. L., Papadimitrakopoulou, V. A., Herbst, R. S., Redman, M. W., Druker, B. J. & Gandara, D. R., Jul 23 2019, In : Blood Advances. 3, 14, p. 2237-2243 7 p.

Research output: Contribution to journalArticle

Open Access
Neoplasms
Research Personnel
Appetite
Epigenomics
Health Personnel

Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies

Schulz, C., Gandara, D. R., Berardo, C. G., Rosenthal, R., Foo, J., Morel, C., Ballinger, M., Watkins, C. & Chu, P., Jan 1 2019, (Accepted/In press) In : Clinical lung cancer.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Immunotherapy
Survival
Neoplasms
docetaxel
1 Citation (Scopus)

EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade

Narayanan, A., Knollmann, F. D., Walby, J. A. S., Lim, S., Gandara, D. R. & Riess, J., Jan 1 2019, (Accepted/In press) In : Clinical Lung Cancer.

Research output: Contribution to journalArticle

Human Herpesvirus 4
Immunotherapy
Carcinoma
Lung
MPDL3280A
13 Citations (Scopus)

Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study

von Pawel, J., Bordoni, R., Satouchi, M., Fehrenbacher, L., Cobo, M., Han, J. Y., Hida, T., Moro-Sibilot, D., Conkling, P., Gandara, D. R., Rittmeyer, A., Gandhi, M., Yu, W., Matheny, C., Patel, H., Sandler, A., Ballinger, M., Kowanetz, M. & Park, K., Jan 1 2019, In : European Journal of Cancer. 107, p. 124-132 9 p.

Research output: Contribution to journalArticle

docetaxel
Non-Small Cell Lung Carcinoma
Survivors
Survival
MPDL3280A